Download PDF
Thromb Haemost 2000; 83(06): 956-961
DOI: 10.1055/s-0037-1613949
Commentary
Schattauer GmbH

CD9 Gene Deficiency Does not Affect Smooth Muscle Cell Migration and Neointima Formation after Vascular Injury in Mice

H. R. Lijnen
1   From the Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
,
F. Lupu
2   Vascular Biology Laboratory, Weston Centre for Experimental Research, Thrombosis Research Institute, London, UK
,
D. Collen
1   From the Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
,
F. Le Naour
3   INSERM Unité 268, Hôpital Paul-Brousse, Villejuif, France
,
C. Boucheix
3   INSERM Unité 268, Hôpital Paul-Brousse, Villejuif, France
› Author Affiliations
Further Information

Publication History

Received 24 January 2000

Accepted after revision 29 February 2000

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

The hypothesis that CD9, a member of the tetraspanin family, plays a role in smooth muscle cell (SMC) migration was tested with the use of a vascular injury model in wild-type (CD9+/+) and CD9-deficient (CD9−/−) mice. Neointima formation 3 weeks after electric injury of the femoral artery was not significantly different in CD9+/+ and CD9−/− mice (area of 0.019 ± 0.0034 mm2 versus 0.013 ± 0.0036 mm2; mean ± SEM, n = 6). The medial areas were also comparable, resulting in intima/media ratio’s of 1.3 ± 0.15 and 0.90 ± 0.22, respectively. Nuclear cell counts in cross-sectional areas of the injured region were comparable in media (33 ± 5 versus 27 ± 2) and neointima (135 ± 16 versus 97 ± 17) of CD9+/+ and CD9−/− arteries. Immunocytochemical analysis revealed expression of CD9 in the endothelium, by SMC in the media and by some fibroblasts in the adventitia of non-injured femoral arteries. Three weeks after injury, there appeared to be a gradient of increased CD9 expression from the adventitia to the neointima, in which SMC are abundantly present. Immunogold labeling and electron microscopy with non-injured femoral arteries of CD9+/+ mice confirmed the presence of CD9 at the surface of adventitial fibroblasts and in SMC or pericytes, as well as in the endothelium.

Thus, in this model CD9 is highly expressed by migrating SMC, but deficiency of CD9 does not affect SMC migration or neointima formation after perivascular injury.

Key words

CD9 - tetraspanin - vascular injury - restenosis - gene-deficient mice
 

  • References

  • 1 Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86 III 47-52.
    CrossrefPubMedGoogle Scholar
  • 2 Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia-a review. J Vasc Surg 1991; 13: 885-91.
    PubMedGoogle Scholar
  • 3 Reidy MA, Jackson D, Lindner V. Neointimal proliferation: control of vascular smooth muscle cell growth. Vasc Med Rev 1992; 03: 156-67.
    PubMedGoogle Scholar
  • 4 Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
    CrossrefPubMedGoogle Scholar
  • 5 Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992; 667: 141-50.
    CrossrefPubMedGoogle Scholar
  • 6 Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996; 78: 405-14.
    CrossrefPubMedGoogle Scholar
  • 7 Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992; 288: 93-9.
    CrossrefPubMedGoogle Scholar
  • 8 Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-45.
    CrossrefPubMedGoogle Scholar
  • 9 Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20: 209-17.
    CrossrefPubMedGoogle Scholar
  • 10 Aoyagi M, Yamamoto M, Azuma H, Nayashima G, Niimi Y, Tamaki M, Hirakawa K, Yamamoto K. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation. Histochem Cell Biol 1998; 109: 97-102.
    CrossrefPubMedGoogle Scholar
  • 11 Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol 1997; 17: 1837-44.
    CrossrefPubMedGoogle Scholar
  • 12 Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 1997; 96: 3555-60.
    CrossrefPubMedGoogle Scholar
  • 13 Carmeliet P, Moons L, Stassen JM, Van Vlaenderen I, Declercq C, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular injury in mice. Am J Pathol 1997; 150: 761-6.
    PubMedGoogle Scholar
  • 14 Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-8.
    CrossrefPubMedGoogle Scholar
  • 15 Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen HR, Collen D. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-39.
    CrossrefPubMedGoogle Scholar
  • 16 Engel LC, Boucheix C, Worthington RE. CD9 antigen is involved with human smooth muscle cell migration. Blood 1993; 82: 281a.
    PubMedGoogle Scholar
  • 17 Forsyth KD. Anti-CD9 antibodies augment neutrophil adherence to endothelium. Immunology 1991; 72: 292-6.
    PubMedGoogle Scholar
  • 18 Masellis-Smith A, Shaw ARE. CD9-regulated adhesion. Anti-CD9 monoclonal antibody induce pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J Immunol 1994; 152: 2768-77.
    PubMedGoogle Scholar
  • 19 Horejsi V, Vleck C. Novel structurally distinct family of leukocyte surface glycoproteins including CD9, CD37, CD53, and CD63. FEBS Lett 1991; 288: 1-4.
    CrossrefPubMedGoogle Scholar
  • 20 Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994; 15: 588-94.
    CrossrefPubMedGoogle Scholar
  • 21 Sincock PM, Mayrhofer G, Ashman LK. Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and α5β1 integrin. J Histochem Cytochem 1997; 45: 515-25.
    CrossrefPubMedGoogle Scholar
  • 22 Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11: 428-42.
    CrossrefPubMedGoogle Scholar
  • 23 Berditchevski F, Zutter MM, Hemler ME. Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell 1996; 07: 193-207.
    CrossrefPubMedGoogle Scholar
  • 24 Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associate with integrin α4β1 (CD49d/CD29). J Immunol 1996; 157: 2039-47.
    PubMedGoogle Scholar
  • 25 Olweus J, Lund-Johansen F, Horejsi V. CD53, a protein with four membrane-spanning domains, mediates signal transduction in human monocytes and B cells. J Immunol 1993; 151: 707-16.
    PubMedGoogle Scholar
  • 26 Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C. CD9 antigen is an accessory subunit of the VLA integrin complexes. Eur J Immunol 1994; 24: 3005-13.
    CrossrefPubMedGoogle Scholar
  • 27 Scherberich A, Moog S, Haan-Archipoff G, Azorsa DO, Lanza F, Beretz A. The tetraspanin CD9 is associated with very late-acting integrins in human vascular smooth muscle cells and modulates collagen matrix reorganization. Arterioscler Thromb Vasc Biol 1998; 18: 1691-7.
    CrossrefPubMedGoogle Scholar
  • 28 Le Naour F, Rubinstein E, Jasmin C, Prenant M, Boucheix C. Severely reduced female fertility in CD9-deficient mice. Science 2000; 287: 319-21.
    CrossrefPubMedGoogle Scholar
  • 29 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
    CrossrefPubMedGoogle Scholar
  • 31 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
    CrossrefPubMedGoogle Scholar
  • 32 Nakamura K, Iwamoto R, Mekada E. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphteria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin α3β1 at cell-cell contact sites. J Cell Biol 1995; 129: 1691.
    CrossrefPubMedGoogle Scholar
  • 33 Rubinstein E, Le Naour F, Lagaudrière-Gesbert C, Billard M, Conjeaud H, Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 1996; 26: 2657-65.
    CrossrefPubMedGoogle Scholar